Analystreport

Adaptimmune Therapeutics plc (NASDAQ: ADAP) had its price target lowered by analysts at Wells Fargo & Company from $7.00 to $1.50. They now have an "equal weight" rating on the stock.

Adaptimmune Therapeutics plc - American Depositary Shares  (ADAP) 
Last adaptimmune therapeutics plc - american depositary shares earnings: 5/9 07:30 am Check Earnings Report